Muhammad Assad Aslam

Muhammad Assad Aslam

Auto-generated profile, based on publicly available information

Muhammad Assad Aslam

Division of Tumor Biology and Immunology, Netherlands Cancer Institute, 1066CX Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
EKEliza Mari Kwesi-Maliepaard
Eliza Mari Kwesi-Maliepaard
MAMuhammad Assad Aslam
Muhammad Assad Aslam
MAMir Farshid Alemdehy
Mir Farshid Alemdehy
TBTeun van Den Brand
Teun van Den Brand
CMChelsea McLean
Chelsea McLean
HJHeinz Jacobs
Heinz Jacobs
Significance: Cytotoxic CD8 + T cells control infectious diseases as well as cancer. Memory T cells are a subset of CD8 + T cells that have previously encountered and rapidly responded to a specific antigen. Here we identified the epigenetic writer DOT1L as a central regulator of T cell physiology. In the absence of DOT1L, which methylates histone H3K79 at active genes, cytotoxic T cells prematurely acquired memory features without having encountered an antigen. However, loss of DOT1L in the T cell lineage led to a compromised immune response. Our findings highlight the importance of epigenetic signals in regulating T cell differentiation. Understanding these epigenetic signals is important for developing strategies to modulate T cell immunity.

7 January 2021 in EMBO Reports
Verified
Journal Article
Open access
PDF file
MAMuhammad Assad Aslam
Muhammad Assad Aslam
MAMir Farshid Alemdehy
Mir Farshid Alemdehy
EKEliza Mari Kwesi-Maliepaard
Eliza Mari Kwesi-Maliepaard
FMFitriari Izzatunnisa Muhaimin
Fitriari Izzatunnisa Muhaimin
MCMarieta Caganova
Marieta Caganova
FLFred van Leeuwen
Fred van Leeuwen
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

17 April 2025 in Blood
Verified
Journal Article
Open access
CGCamiel Göbel
Camiel Göbel
RNRachele Niccolai
Rachele Niccolai
MGMarnix H. P. de Groot
Marnix H. P. de Groot
JJJayashree Jayachandran
Jayashree Jayachandran
JTJoleen Traets
Joleen Traets
HJHeinz Jacobs
Heinz Jacobs
Differentiation of antigen-activated B cells into proproliferative germinal center (GC) B cells depends on the activity of the transcription factors myelocytoma (MYC) and B-cell lymphoma 6 (BCL6), and the epigenetic writers disruptor of telomeric silencing 1-like (DOT1L) and enhancer of zeste homolog 2 (EZH2). GCB-like diffuse large B-cell lymphomas (GCB-DLBCLs) arise from GCB cells and closely resemble their cell of origin. Given the dependency of GCB cells on DOT1L and EZH2, we investigated the role of these epigenetic regulators in GCB-DLBCLs and observed that GCB-DLBCLs synergistically depend on the combined activity of DOT1L and EZH2. Mechanistically, inhibiting both enzymes led to enhanced derepression of polycomb repressive complex 2 target genes compared with EZH2 single treatment, along with the upregulation of BCL6 target genes and suppression of MYC target genes. The sum of all these alterations results in a “cell identity crisis,” wherein GCB-DLBCLs lose their proproliferative GC identity and partially undergo plasma cell differentiation, a state associated with poor survival. In support of this model, combined epidrugging of DOT1L and EZH2 prohibited the outgrowth of human GCB-DLBCL xenografts in vivo. We conclude that the malignant behavior of GCB-DLBCLs strongly depends on DOT1L and EZH2 and that combined targeting of both epigenetic writers may provide an alternative differentiation-based treatment modality for GCB-DLBCL.

12 December 2025 in Science Advances
Verified
Journal Article
Open access
MMMuddassir Malik
Muddassir Malik
WLWillem-Jan de Leeuw
Willem-Jan de Leeuw
MAMuhammad Assad Aslam
Muhammad Assad Aslam
EKEliza Mari Kwesi-Maliepaard
Eliza Mari Kwesi-Maliepaard
TBTeun van Den Brand
Teun van Den Brand
FLFred van Leeuwen
Fred van Leeuwen
The histone methyltransferase DOT1L is emerging as a central epigenetic regulator in immune cells. Loss of DOT1L during development of CD8 T cells in vivo leads to gain of memory characteristics but has also been reported to compromise CD8 T cell viability and antitumor reactivity. Here, we determined the cell-intrinsic role of DOT1L in mature mouse CD8 T cells. After conditional deletion of Dot1L in vitro, CD8 T cells retained in vivo proliferative capacity and antitumor reactivity. Moreover, Dot1L knockout CD8 T cells showed increased antigen-specific cytotoxicity toward tumor cells in vitro. Mechanistically, loss of DOT1L resulted in an altered cell state with loss of T cell and gain of innate-like features. These transcriptional changes were mediated by loss of DOT1L methyltransferase activity in a dose-dependent manner. Our findings show that in mature CD8 T cells, ablation of DOT1L activity is well tolerated and reprograms them to gain innate-like memory cell characteristics and enhance intrinsic cytotoxic capacity.

23 November 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
MAMuhammad Assad Aslam
Muhammad Assad Aslam
MAMir Farshid Alemdehy
Mir Farshid Alemdehy
BHBingtao Hao
Bingtao Hao
PKPeter H. L. Krijger
Peter H. L. Krijger
CPColin E. J. Pritchard
Colin E. J. Pritchard
HJHeinz Jacobs
Heinz Jacobs
Significance: Immunoglobulin heavy chain checkpoint (IgHCC) is a critical step during early B cell development. The role of immunoglobulin heavy chain (IgHC) at this step is well established. However, with the expanding knowledge of RNA in regulating central biological processes, there could be a noncoding contribution of IgHC mRNA ( IgHR ) in controlling the IgHCC. Here, we generated a novel mouse model that enabled us to determine a potential role of IgHR in the IgHCC, independent of IgHC signaling. Our data indicate that IgHR has no role in IgHCC and the latter is predominantly controlled by IgHC, as proposed earlier. Furthermore, this study highlights the sensitivity of progenitor B cells to low amounts of IgHC.

22 January 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
MMMuddassir Malik
Muddassir Malik
WLWillem-Jan de Leeuw
Willem-Jan de Leeuw
MAMuhammad Assad Aslam
Muhammad Assad Aslam
EKEliza Mari Kwesi-Maliepaard
Eliza Mari Kwesi-Maliepaard
TBTeun van Den Brand
Teun van Den Brand
FLFred van Leeuwen
Fred van Leeuwen
The histone methyltransferase DOT1L is emerging as a central epigenetic regulator in immune cells. Loss of DOT1L during development of CD8 T cells in vivo leads to gain of memory-features but has also been reported to compromise CD8 T cell viability and activity. Here, we determined the cell-intrinsic role of DOT1L in mature mouse CD8 T cells. After conditional deletion of Dot1L in vitro, CD8 T cells retained in vivo proliferative capacity and anti-tumor reactivity. Moreover, Dot1L knock-out CD8 T cells showed increased antigen-specific cytotoxicity towards tumor cells in vitro. Mechanistically, loss of DOT1L resulted in an altered cell-identity program with loss of T-cell and gain of NK-cell features. These transcriptional changes were mediated by loss of DOT1L methyltransferase activity in a dose-dependent manner. Our findings show that ablation of DOT1L activity in mature CD8 T cells is well-tolerated and rewires their cell identity towards the NK-cell lineage, concomitantly enhancing intrinsic cytotoxic capacity. Highlights: Differentiation and identity of cytotoxic T cells depend on the methyltransferase DOT1L DOT1L intrinsically limits the cytotoxic activity of mature CD8 T cells DOT1L prohibits the acquisition of NK cell features in CD8 T cells DOT1L maintains CD8 T cell identity through its catalytic activity in a dose-dependent manner